CVS Pharmacy to Pay $315 Million to Settle DOJ Opioid Prescription Case

CVS Pharmacy Inc. and various subsidiaries have agreed to pay $315 million to resolve a Department of Justice lawsuit alleging the company unlawfully dispensed medically unnecessary prescriptions for highly addictive opioids and other controlled substances. The suit, filed by the Biden administration in 2024, accused CVS of knowingly filling opioid prescriptions without a legitimate medical purpose, dispensing drugs in excessive quantities including so-called "trinity" combinations of an opioid, a benzodiazepine and a muscle relaxant, and imposing performance metrics that prioritized pharmacy profits over patient safety. Prosecutors also alleged the company prevented pharmacists from sharing warnings about problematic prescribers.

CVS said it admitted no wrongdoing and strongly disagreed with the claims, stating its pharmacists were trained in the safe and appropriate use of medications and that the company had implemented programs to support sound prescribing decisions. Associate Attorney General Stanley Woodward called the settlement "a significant milestone in the Justice Department's efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances."

The settlement adds to a substantial financial toll CVS has already faced over opioid-related litigation. The company has now paid roughly $5 billion to settle lawsuits claiming it mishandled opioid prescribing, and total opioid settlements across companies, states, municipalities and tribal governments have surpassed $58 billion according to the Opioid Settlement Tracker. CVS's remaining accrual for opioid litigation matters stood at approximately $4.0 billion as of March 31, 2026, with litigation still pending in Maryland, Philadelphia and with other non-participating jurisdictions.